AR027122A1 - Composicion paa el tratamiento de tejidos danados - Google Patents
Composicion paa el tratamiento de tejidos danadosInfo
- Publication number
- AR027122A1 AR027122A1 ARP000106960A ARP000106960A AR027122A1 AR 027122 A1 AR027122 A1 AR 027122A1 AR P000106960 A ARP000106960 A AR P000106960A AR P000106960 A ARP000106960 A AR P000106960A AR 027122 A1 AR027122 A1 AR 027122A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- composition
- donated
- fabrics
- wound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un agente farmacéutico para uso en el tratamiento (por ejemplo, curacion) de tejidos danados, tal como una herida, comprendiendo el agentefarmacéutico una composicion que comprende: (a) un factor de crecimiento; (b) un agente inhibidor; y , opcionalmente (c) un vehículo, diluyente o excipientefarmacéuticamente aceptable; pudiendo el agente inhibidor inhibir la accion de al menos una porteína adversa específica (por ejemplo, una proteasa específica)que está regulada positivamente en un entorno de tejido danado, tal como una herida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930768.8A GB9930768D0 (en) | 1999-12-29 | 1999-12-29 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027122A1 true AR027122A1 (es) | 2003-03-12 |
Family
ID=10867127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106960A AR027122A1 (es) | 1999-12-29 | 2000-12-27 | Composicion paa el tratamiento de tejidos danados |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1242120A2 (es) |
JP (1) | JP2003519193A (es) |
AR (1) | AR027122A1 (es) |
AU (1) | AU1878201A (es) |
CA (1) | CA2395487A1 (es) |
CO (1) | CO5271671A1 (es) |
EC (1) | ECSP003859A (es) |
GB (1) | GB9930768D0 (es) |
GT (1) | GT200000224A (es) |
PE (1) | PE20011095A1 (es) |
UY (1) | UY26514A1 (es) |
WO (1) | WO2001049309A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
ES2304401T3 (es) | 2000-10-16 | 2008-10-16 | Genentech, Inc. | Metodos de tratamiento que utilizan polipeptidos wisp. |
CN100509055C (zh) | 2001-07-27 | 2009-07-08 | 奥索洛吉艾斯有限公司 | 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 |
WO2003029819A1 (fr) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Procede pour le criblage preventif / le traitement des maladies d'os ou d'articulations |
JP2006514822A (ja) | 2002-07-02 | 2006-05-18 | ザ ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | トロンビンペプチド誘導体 |
DK1559431T3 (da) | 2003-12-31 | 2007-07-30 | Orthologic Corp | Farmaceutisk sammensætning til thrombinpeptidderivater |
CN101365715B (zh) | 2005-10-07 | 2013-03-27 | P·安杰莱蒂分子生物学研究所 | 基质金属蛋白酶11疫苗 |
KR20100027091A (ko) * | 2006-11-15 | 2010-03-10 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
KR101629504B1 (ko) * | 2014-04-14 | 2016-06-10 | 주식회사 엘지생활건강 | 사이토카인 조합을 함유하는 피부 상태 개선용 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01279840A (ja) * | 1988-04-28 | 1989-11-10 | Wakunaga Pharmaceut Co Ltd | 新規外用組成物 |
GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
-
1999
- 1999-12-29 GB GBGB9930768.8A patent/GB9930768D0/en not_active Ceased
-
2000
- 2000-12-21 AU AU18782/01A patent/AU1878201A/en not_active Abandoned
- 2000-12-21 EP EP00981550A patent/EP1242120A2/en not_active Withdrawn
- 2000-12-21 JP JP2001549676A patent/JP2003519193A/ja not_active Withdrawn
- 2000-12-21 CA CA002395487A patent/CA2395487A1/en not_active Abandoned
- 2000-12-21 WO PCT/IB2000/001935 patent/WO2001049309A2/en not_active Application Discontinuation
- 2000-12-21 CO CO00097188A patent/CO5271671A1/es not_active Application Discontinuation
- 2000-12-22 GT GT200000224A patent/GT200000224A/es unknown
- 2000-12-27 PE PE2000001405A patent/PE20011095A1/es not_active Application Discontinuation
- 2000-12-27 AR ARP000106960A patent/AR027122A1/es not_active Application Discontinuation
- 2000-12-28 EC EC2000003859A patent/ECSP003859A/es unknown
- 2000-12-28 UY UY26514A patent/UY26514A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU1878201A (en) | 2001-07-16 |
PE20011095A1 (es) | 2001-10-27 |
JP2003519193A (ja) | 2003-06-17 |
GB9930768D0 (en) | 2000-02-16 |
CA2395487A1 (en) | 2001-07-12 |
WO2001049309A3 (en) | 2002-02-28 |
GT200000224A (es) | 2002-06-15 |
ECSP003859A (es) | 2002-09-27 |
EP1242120A2 (en) | 2002-09-25 |
WO2001049309A2 (en) | 2001-07-12 |
CO5271671A1 (es) | 2003-04-30 |
UY26514A1 (es) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0200782A (pt) | Compostos para o tratamento da isquemia | |
AR010385A1 (es) | Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto. | |
BR0207760A (pt) | Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
DOP2000000114A (es) | Oxazolidinonas substituidas y su uso | |
ES2065471T3 (es) | Composiciones acuosas antibacterianas que comprenden un tensoactivo y bacteriofagos. | |
AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
PE20010286A1 (es) | Derivados de indoloxoacetil piperazina como agentes antivirales | |
BR0014384A (pt) | Compostos para o tratamento da isquémia | |
ATE218581T1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
AR007582A1 (es) | Composicion para el lavado de la piel, procedimiento para prepararla y el uso de la misma para la fabricacion de medicamentos dado el caso, para eltratamiento cosmetico de la piel. | |
ES2083597T3 (es) | Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado. | |
AR027122A1 (es) | Composicion paa el tratamiento de tejidos danados | |
MD20020075A (en) | Antimicrobial preparation with retarded release of the biologically active component, utilization thereof and process for implant obtaining | |
ES2173923T3 (es) | Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente. | |
ES2174921T3 (es) | Inhibidores de la proteasa del vih. | |
ECSP930933A (es) | Composicion farmaceutica y procedimiento para prepararla | |
AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
DE69909747D1 (de) | Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen | |
AU2001238332A1 (en) | Method of sterilizing articles | |
AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
AR005730A1 (es) | Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato. | |
CO5271686A1 (es) | Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |